[[{“value”:”
Revolution Medicines drug RMC-6236 increased progression-free survival in patients with advanced cases of pancreatic ductal adenocarcinoma. With these results, the biotech is preparing for a Phase 3 clinical trial in this indication, the most common type of pancreatic cancer.
The post Positive Data in Pancreatic Cancer Pave Way for Pivotal Test of Revolution Medicines Drug appeared first on MedCity News.
“}]]
